Plaque psoriasis drug outshines the competition in phase III trial
Bristol Myers Squibb’s psoriasis drug, the TYK2 inhibitor outshone placebo and Amgen’s Otezla in a second phase 3 study, setting discussions with regulators.
The study, known as POETYK PSO-2, trialled the drug, deucravacitinib, against placebo and Otezla in 1,020 patients with moderate to severe plaque psoriasis as per announced by the company. After 16 weeks of treatment, remarkably more patients taking Bristol Myers’ drug than placebo had a 75% depletion of psoriasis area and severity and clear or almost transparent skin as measured by the static Physician’s Global Assessment, a visual evaluati...
